Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 15/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 5/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.35 |
| ▸ | ITGAL | P20701 | 5/20 | 0.35 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.32 |
| ▸ | ITGAV | P06756 | 3/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016399 | 0.93 | ITGB1 (0.36) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22017535 | 0.92 | ITGB1 (0.36) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22016310 | 0.90 | ITGB1 (0.35) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22016649 | 0.88 | ITGB1 (0.38) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22016333 | 0.88 | ITGB1 (0.37) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22016400 | 0.88 | ITGB2 (0.35) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22016395 | 0.88 | ITGB2 (0.35) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22017003 | 0.87 | ITGB2 (0.38) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22017218 | 0.87 | ITGB2 (0.35) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22016657 | 0.86 | ITGB2 (0.34) | ITGB1ITGA4ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ITGB1 3359/4885ITGA4 3235/4885ITGB2 2856/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ITGB1 3359/4885ITGA4 3235/4885ITGB2 2856/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | ITGB1 2/4885ITGA4 4/4885ITGB2 7/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | ITGB1 3359/4885ITGA4 3235/4885ITGB2 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.